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Key messages
 ► Systematic review evidence from a small number of 
randomised controlled trials (RCTs) suggested that 
discharge bundles for patients with chronic obstruc-
tive pulmonary disease (COPD) lead to fewer read-
missions but do not significantly improve mortality 
or quality of life. Few data are available on admission 
bundles for COPD.
 ► This study found that admission and discharge 
care bundles for COPD had little impact on patient 
outcomes, including readmissions and mortality or 
healthcare costs, but appeared to be associated with 
a reduced number of subsequent attendances at the 
emergency department.
 ► Evaluation of ‘real world’ implementation of ad-
mission and discharge care bundles highlighted 
the challenge of effective implementation of COPD 
bundles and does not replicate the effectiveness of 
implementing care bundles demonstrated in RCTs.
AbstrAct
background Chronic obstructive pulmonary disease 
(COPD) accounts for 10% of emergency hospital 
admissions in the UK annually. Nearly 33% of patients 
are readmitted within 28 days of discharge. We evaluated 
the effectiveness of implementing standardised packages 
of care called ‘care bundles’ on COPD readmission, 
emergency department (ED) attendance, mortality, costs 
and process of care.
Methods This is a mixed-methods, controlled before-and-
after study with nested case studies. 31 acute hospitals in 
England and Wales which introduced COPD care bundles 
(implementation sites) or provided usual care (comparator 
sites) were recruited and provided monthly aggregate 
data. 14 sites provided additional individual patient 
data. Participants were adults admitted with an acute 
exacerbation of COPD.
results There was no evidence that care bundles reduced 
28-day COPD readmission rates: OR=1.02 (95% CI 0.83 
to 1.26). However, the rate of ED attendance was reduced 
in implementation sites over and above that in comparator 
sites (implementation: IRR=0.63 (95% CI 0.56 to 0.71); 
comparator: IRR=1.12 (95% CI 1.02 to 1.24); group–time 
interaction p<0.001). At implementation sites, delivery of 
all bundle elements was higher but was only achieved in 
2.2% (admissions bundle) and 7.6% (discharge bundle) of 
cases. There was no evidence of cost-effectiveness. Staff 
viewed bundles positively, believing they help standardise 
practice and facilitate communication between clinicians. 
However, they lacked skills in change management, 
leading to inconsistent implementation.
Discussion COPD care bundles were not effectively 
implemented in this study. They were associated with a 
reduced number of subsequent ED attendances, but not 
with change in readmissions, mortality or reduced costs. 
This is unsurprising given the low level of bundle uptake 
in implementation sites, and it remains to be determined if 
COPD care bundles affect patient care and outcomes when 
they are effectively implemented.
trial registration number ISRCTN13022442.
IntroDuctIon
Chronic obstructive pulmonary disease 
(COPD) is one of the most common 
respiratory diseases in the UK, with an esti-
mated prevalence of 1.2 million people.1 
Globally, the estimated prevalence of COPD 
was 251 million cases in 2016, and it is esti-
mated that 3.17 million deaths were caused 
by the disease in 2015, which is 5% of all 
deaths.2 COPD accounts for 10% of emer-
gency hospital admissions in the UK, and the 
number of admissions has increased by 50% 
in the last decade.1 3 A third of these patients 
are readmitted within 28 days of discharge.3 
COPD admissions are estimated to cost the 
National Health Service (NHS) £491 million 
per year.
The care provided for COPD varies across 
European countries, and an audit in the 
NHS highlighted wide variation in treatment 
provision and outcomes for patients admitted 
for COPD.4 5 This disparity was particularly 
marked in relation to mortality. It also showed 
that a significant proportion of the observed 
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variability could be explained by access to expert care 
and evidence-based interventions. There is, therefore, 
opportunity to improve outcomes for patients with 
COPD by ensuring that care is consistently provided to 
a high standard.
The Institute for Healthcare Improvement developed 
the concept of care bundles with the aim of improving 
care processes to the highest levels of reliability, which 
would result in improved outcomes.6 A care bundle can 
be defined as a set of evidence-based clinical interven-
tions or actions which when performed reliably improve 
patient outcomes. Admission and discharge care bundles 
for COPD were developed by the British Thoracic Society 
(BTS) in association with NHS Improvement.7 The aim 
of the admission care bundle is to reduce in-hospital 
mortality and length of stay, and the discharge care 
bundle was designed to reduce readmissions. Early pilots 
in the UK prior to this study suggested possible benefits 
from care bundles in COPD and other conditions.8 9 A 
single site evaluation of COPD admission care bundles 
showed delivery of care was improved in the emergency 
department (ED).10 Further studies and a systematic 
review have focused on discharge bundles, suggesting 
a reduction in readmissions but highlighting that the 
impact of care bundles on processes and outcomes of 
care is poorly understood.11–14
This study evaluated the effectiveness of introducing 
admission and discharge care bundles for patients with 
an acute exacerbation of COPD (AECOPD) as a means of 
improving hospital care, and reducing readmissions and 
mortality, and explored the impact on cost of care and 
patient and staff experience.
MethoDs
Design
We conducted a mixed-method evaluation using a 
controlled before-and-after design with nested qualitative 
case studies to examine the effect of implementing care 
bundles (online supplementary figure 1). The study was 
conducted between 2014 and 2017. More details about 
the study methodology can be found in the published 
protocol paper.15
setting and sampling
We recruited 31 acute hospitals in England and Wales to 
the study, approaching sites via the BTS and the National 
Institute for Health Research Clinical Research Network. 
This included 19 sites which either introduced care 
bundles during the study period or used care bundles 
routinely in COPD care (implementation sites), and 12 
sites which provided ‘usual care’ throughout the study 
period (comparator sites). An ‘index date’ was defined for 
all sites based on when they implemented the bundles—
in the case of implementation sites—or the implementa-
tion date of a similar site in the comparator sites. Appli-
cation of a quality improvement (QI) methodology was 
encouraged in implementation sites throughout the 
duration of the study using video-conferencing, face-to-
face training sessions and one-to-one mentoring.7
A subset of these sites provided pseudoanonymised 
details of all individual patient-level admissions over a 
period of 12 months preindex and postindex date. With 
seven pairs of similar implementation and comparator 
sites, it was estimated that there would be a sample of 
approximately 10 000 admissions per year. Assuming 
30% of patients were readmitted in comparator sites, this 
would allow us to detect a 9% absolute difference in the 
COPD readmission rate at 28 days with 90% power and 
5% significance level.
Data collection
Each site was asked to provide data covering a 24-month 
period—12 months prior to their implementation index 
date and 12 months afterwards. All sites provided monthly 
aggregated, routinely collected, Trust-level data for this 
period (level 1 data). The data included COPD admis-
sions rates, COPD readmission at 28 days and 90 days, 
mortality, length of stay, ED attendances, and delivery of 
bundle elements where appropriate. COPD admissions 
were identified as those with International Classification 
of Diseases 10th Revision codes J41-44 in the first episode 
of care.7
Sites providing pseudoanonymised patient-level data 
(level 2) reported outcomes, sociodemographic, clinical 
and procedure codes plus the information gathered for 
level 1 sites. Demographic data on individual patients 
allowed us to study the characteristics of patients admitted 
with AECOPD and adjust for these in analyses. Each level 
2 site was also asked to provide details from the case 
notes of a random sample of 140 postindex date COPD 
admissions to provide data on the delivery of the various 
components of the care bundles (n=2240). Quantitative 
data submitted to the research team were compiled and 
checked for both validity and consistency.
Qualitative data were collected from six level 3 sites 
about the process of bundle implementation or usual 
care. In addition, data on the context in which bundles 
were delivered, and the impact on staff, patients and 
carers, were collected by KM and AK. Methods used 
to capture data at these four implementation and two 
comparator sites included document analysis, non-partic-
ipant observation of patient care, and indepth interviews 
with health professionals, patients and carers following 
both admission and discharge, guided by topic guides 
and observation schedules.
care bundle components
The following were the components of the BTS admis-
sion bundle:
 ► A correct diagnosis of AECOPD to be confirmed.
 ► An oxygen assessment should be undertaken and the 
correct target range prescribed within 30 min.
 ► Recognise and respond to respiratory acidosis within 
1 hour of admission.
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 ► Medication (steroids and nebulisers) to be adminis-
tered within 4 hours of admission.
 ► Review by respiratory team to take place within 24 
hours of admission.
The following were the components of the BTS 
discharge bundle:
 ► Patients should have respiratory medications and 
inhaler technique assessed prior to discharge.
 ► All patients should receive a written plan for how 
to manage a further AECOPD and should receive 
a discharge pack of ‘emergency’ drugs prior to 
discharge.
 ► Smoking status should be assessed together with a 
willingness to quit, and for those patients indicating a 
wish for further assistance a referral should be made 
to a stop smoking programme.
 ► All patients should be assessed for their suitability for 
pulmonary rehabilitation prior to discharge.
 ► Community follow-up within 2 weeks of discharge 
from hospital should be organised.
Data analysis
Quantitative analysis of effectiveness data
Trust-level aggregate outcomes were reported monthly 
for the 12 months before and after their index date. 
These monthly data were used to calculate the mean 
change of all outcome measures postindex date at each 
site. This mean change was then compared between 
implementation and comparator sites using linear 
regression analyses on monthly outcomes to estimate 
how the change postindex date differed between 
implementation and comparator sites after adjustment 
for the number of COPD admissions, overall 28-day 
readmission rate and in-hospital mortality rates in the 
preindex date period.
The characteristics of patients having at least one COPD 
admission in the preindex date period were compared 
between implementation and comparison sites. Linear, 
logistic and ordered logistic regression models with SEs 
adjusted for Trust-level clustering were used to test for 
differences between groups.
Individual-level patient outcomes were studied using 
a range of multilevel regression models to compare 
the change in outcomes postindex date using an indi-
cator variable (preindex or postindex date) between 
the implementation and comparator sites. These anal-
yses controlled for clustering within observations from 
the same patient and within each Trust using random 
effects for patient and Trust. Multilevel logistic regres-
sion models were used for binary outcomes. Where 
logistic regression failed to converge, multilevel Poisson 
models with robust SEs were used. Multilevel negative 
binomial regression models were used for length of stay 
and number of emergency admissions due to a large vari-
ance in outcome. Models were first run without adjust-
ment for potential confounding, then rerun adjusting 
for age, sex, ethnicity and Index of Multiple Deprivation 
quintile. For each logistic regression analysis, ORs and 
95% CIs were presented, while for negative binomial 
and Poisson models the incidence rate ratios (IRRs) and 
95% CIs were presented. No formal adjustment was made 
for multiple testing. Likelihood ratio tests (or Wald tests 
where robust SEs were used) were used to test for the 
presence of group–time interaction.
The extent to which sites implemented each element 
of the bundle was recorded using case note extraction 
data, and the results were summarised by group using 
frequencies and proportions. χ2 tests were used to 
compare the proportion of patients receiving bundle 
elements between implementation and comparator sites.
Qualitative analysis
Interviews with staff, patients and carers and observa-
tional data from level 3 sites were collected, anonymised 
and uploaded into NVivo.16 All qualitative data were 
examined using cross-case thematic analysis and analysed 
both inductively and deductively.17 The analysis sought to 
identify similarities and differences between sites, high-
lighting aspects which might be transferable to other 
hospitals intending to implement care bundles. Atten-
tion was also given to overlaps or divergence between 
aspects of practice observed.
Quantitative analysis of cost-effectiveness data
An economic evaluation considering the 90-day period 
following the index admission for COPD was under-
taken in level 2 sites. We estimated per-patient secondary 
care NHS costs using healthcare resource group unit 
costing methodology,18 where patient-specific resource 
use was valued using nationally representative sources, 
for example, NHS reference costs,19 the British National 
Formulary,20 and Unit Costs of Health and Social Care.21 
In the absence of individual-level data on self-reported 
quality of life or other outcome measures, 90-day 
mortality following the index admission served as the 
main outcome measure for the cost-effectiveness anal-
ysis. This permits the incremental costs associated with 
care bundles to be associated with incremental deaths 
avoided. Cost-effectiveness was calculated as a ratio of the 
difference in NHS secondary care costs between interven-
tion and comparator sites to the between-site differences 
in 90-day mortality. Detailed methods are described in 
the protocol paper15 and study report.22
Patient and public involvement
Throughout the 40-month study, the research team 
conducted a range of patient and public involvement 
(PPI) activities to ensure that the protocol was properly 
implemented and that any findings were appropriately 
interpreted in the light of patient and carer experience. 
Patients and carers were involved in suggesting the orig-
inal idea for the study, then commenting on the applica-
tion for funding, including aims and objectives, methods 
and PPI. An active PPI group was then formed which 
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Table 1 Trust-level outcomes (monthly) pooled across implementation and comparator sites
Outcome Group Preindex Postindex
Difference in the change 
postindex date between 
implementation and 
comparator sites* (95% CI) P value
Number of COPD admissions, 
mean (SD)
Comparator 48.02 (21.91) 49.33 (19.33) 0.17 (−6.57 to 6.90) 0.960
Implementation 52.49 (18.21) 53.93 (17.94)
28-day COPD readmission rate, 
mean (SD)
Comparator 11.49 (3.60) 12.79 (4.36) −1.31 (−5.37 to 2.75) 0.513
Implementation 15.95 (9.20) 16.07 (11.53)
28-day overall readmission rate, 
mean (SD)
Comparator 23.63 (6.70) 24.91 (7.46) −1.17 (−4.51 to 2.17) 0.478
Implementation 23.05 (9.90) 23.10 (9.96)
90-day COPD readmission rate, 
mean (SD)
Comparator 22.35 (5.59) 23.12 (7.27) −4.00 (−8.87 to 0.87) 0.103
Implementation 25.47 (16.42) 22.38 (11.92)
Number of ED attendances for 
COPD per month, mean (SD)
Comparator 32.45 (25.17) 37.60 (26.69) −3.38 (−14.59 to 7.82) 0.525
Implementation 45.87 (39.27) 47.03 (38.22)
Length of stay, mean (SD) Comparator 6.21 (1.96) 5.95 (1.60) −0.30 (−1.10 to 0.51) 0.453
Implementation 6.76 (1.36) 6.16 (1.17)
Total bed days, mean (SD) Comparator 288.48 (156.30) 275.86 (115.58) 7.83 (−53.66 to 69.32) 0.795
Implementation 333.15 (121.35) 326.37 (136.62)
*Adjusted for the number of COPD admissions, in-hospital mortality and overall 28-day readmission for COPD in the preindex date period.
COPD, chronic obstructive pulmonary disease; ED, emergency department.
continued to provide input on recruitment and patient 
burden during data collection and study documentation 
such as consent forms and information sheets. PPI partic-
ipants also provided feedback on the data available from 
both qualitative and quantitative sources, commenting 
on the extent to which it validated their own experiences 
of care, and provided feedback on possible approaches 
to the dissemination of the results of the study which 
would inform patient groups and the wider community.
results
Quantitative findings
Analysis of Trust-level aggregate data
Nineteen sites implementing COPD care bundles and 11 
comparator sites provided preindex and postindex date 
data for analysis. One other comparator site was unable 
to provide data for the full study period. Pooled results 
are presented in table 1.
Implementation sites had a slightly higher mean 
number of monthly COPD admissions during the 
preindex date period (52.5 vs 48.0) and a slightly higher 
mean monthly readmission rate for COPD (15.2% vs 
11.5%).
When comparing outcomes for readmissions, ED atten-
dances, length of stay and bed days, the change observed 
between the preindex and postindex date periods in 
the implementation sites did not differ from that seen 
in the comparator sites (table 1). Graphs displaying the 
monthly 28-day readmission rates for COPD (preindex 
date) over time by site showed no obvious trends for most 
sides, although for some there was a clear, strong trend 
of an increasing admission rate over the year (online 
supplementary figure 2).
Analysis of individual patient-level data
During the preindex date period, patients in the imple-
mentation sites tended to be slightly younger, although 
the evidence of difference was weak (table 2).
There were 19 097 emergency hospital admissions 
for COPD during the full study period, of which 13.0% 
resulted in a readmission for COPD within 28 days. In the 
preindex date period, 11.6% of COPD admissions had a 
readmission within 28 days in implementation sites. In 
comparator sites, the proportion was 14.7%. Postindex 
date, these proportions were 10.8% in implementation 
sites but remained at 14.7% in comparator sites. In multi-
variable regression analyses, there was no evidence that 
the 28-day readmission rates changed postindex date 
in either the implementation or comparator sites, and 
there was no difference in the changes between these two 
groups (OR for group–time interaction term=1.02 (95% 
CI 0.83 to 1.26); p=0.865) (table 3).
Similar findings were observed for 90-day COPD read-
mission rates and 90-day mortality (table 3). In the case of 
28-day all-cause readmissions, there was weak evidence of 
a reduction in the implementation sites (OR=0.88 (95% 
CI 0.77 to 1.00)), but little evidence that this reduction 
differed from changes observed in the comparator sites 
(group–time interaction term OR=0.88 (95% CI 0.74 to 
1.05); p=0.156) in analyses adjusting for confounders. 
There was only weak evidence that the reduction in the 
length of stay in the implementation sites differed from 
that observed in the comparator sites (group–time inter-
action term OR=0.94 (95% CI 0.88 to 1.01); p=0.100).
Changes in in-hospital mortality rates did not differ 
between comparator sites and implementation sites 
(group–time interaction term OR=1.05 (95% CI 0.77 to 
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Table 2 Characteristics of patients having at least one COPD admission in level 2 implementation and comparator sites at 
preindex date
Characteristics Implementation sites Comparator sites P value
Number of COPD admissions 4657 4515
Number of patients having at least one COPD admission 2732 2549
Age, mean (SD) 71.92 (12.08) 73.02 (11.45) 0.166
Sex, number of male (%) 1351 (49.5) 1240 (48.7) 0.785
Ethnicity, number of patients (%)   
  White 2305 (85.59) 2195 (87.7) 0.748
  Other 388 (14.4) 307 (12.3)
Comorbidity, mean Charlson score (SD) 2.07 (1.58) 2.14 (1.65) 0.673
Socioeconomic status, number of patients per IMD quintile (%)   
  1 (most deprived) 103 (37.0) 930 (38.2) 0.763
  2 552 (20.4) 554 (22.8)
  3 493 (18.2) 506 (20.8)
  4 339 (12.5) 244 (10.0)
  5 (least deprived) 326 (12.0) 198 (8.1)
COPD, chronic obstructive pulmonary disease; IMD, Index of Multiple Deprivation.
1.44); p=0.741). The number of ED attendances after 
an initial emergency admission for COPD increased 
postindex date in the comparator sites (IRR=0.78 (95% 
CI 0.63 to 0.97)) while the rates dropped in the imple-
mentation sites (IRR=0.63 (95% CI 0.56 to 0.71)), and 
there was evidence that the drop was greater in the imple-
mentation sites (group–time interaction term IRR=0.56 
(95% CI 0.48 to 0.65); p<0.001).
Sites provided data on care bundle delivery for 1525 
patients (77.8% of those requested) (table 4). Delivery of 
bundle elements generally occurred more frequently in 
implementation sites than in comparator sites, although 
few patients in implementation sites received all five 
BTS-specified bundle elements (admissions bundle: 2.2%; 
discharge bundle: 7.6% in implementation sites). The 
average number of admission bundle elements received 
in comparator sites was 2.2 (SD=1.1) vs 2.6 (SD=1.1) in 
implementation sites. The average number of individual 
care elements received on discharge in comparator sites 
was 1.8 (SD=1.3) vs 2.8 (SD=1.7) in implementation sites 
(tables 4 and 5).
Qualitative findings
Staff perceptions of care bundles were largely posi-
tive. Bundles were described as useful for standard-
ising working practices, supporting a clear patient care 
pathway, facilitating communication between different 
teams and identifying support required by patients 
following discharge from hospital. Care bundles were 
also perceived by staff as a means for embedding reliable, 
sustainable QI. Staff highlighted the need for managerial 
support, resourcing and regular training to facilitate QI.
It means that they [patients] get the care they need, every 
time, it’s always standard, it’s always how they should be 
and we know it’s always been done. (IMP03 ACU6, Lead 
Nurse, Acute Care)
with a care bundle, there is a better chance they are going to 
go out on the right treatment really, particularly if they have 
not been under the Respiratory Team, and they will have 
access to more services. (IMP11 ACU7, ED Consultant)
I think when patients get discharged I think our checklist that 
we have works really, really well because it’s a good sort of 
pointer for us to try and get patients in to see the appropriate 
people. (COMP06 ACU3, Respiratory Nurse)
Patients and carers highlighted the need for specialist 
care and support at the point of discharge, as well as 
timely follow-up in the community.
I think I’ll be quite happy and contented as long as I know 
I’ll be under the COPD nurses. (IMP05 PAT7, Patient)
The staff data echoed this, by highlighting how pres-
sure around patient numbers, resourcing and staffing 
in the current context of the NHS can mean that it is 
not always possible for patients to receive as thorough 
care, particularly in relation to follow-up, as acute and 
community staff would prefer. Discharge bundles created 
opportunities to discuss available services and potential 
management options.
cost-effectiveness findings
COPD care bundles were very unlikely (probability 
<0.01) to be cost-effective at an arbitrary cost-effective-
ness threshold of £20 000 per death avoided at 90 days 
in a fully adjusted, multiply imputed economic model.
 o
n
 25 June 2019 by guest. Protected by copyright.
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2019-000425 on 30 May 2019. Downloaded from 
6 Morton K, et al. BMJ Open Resp Res 2019;6:e000425. doi:10.1136/bmjresp-2019-000425
Open access
Ta
b
le
 3
 
R
eg
re
ss
io
n 
m
od
el
 r
es
ul
ts
 fo
r 
p
rim
ar
y 
an
d
 s
ec
on
d
ar
y 
ou
tc
om
es
 u
si
ng
 in
d
iv
id
ua
l-
le
ve
l d
at
a 
(le
ve
l 2
)
O
ut
co
m
e
M
o
d
el
C
O
P
D
 a
d
m
is
si
o
ns
 
in
 a
na
ly
si
s 
(n
)
C
ha
ng
e 
p
o
st
in
d
ex
 d
at
e 
in
 
co
m
p
ar
at
o
r 
si
te
s,
 e
st
im
at
e 
(9
5%
 C
I)
C
ha
ng
e 
p
o
st
in
d
ex
 d
at
e 
in
 im
p
le
m
en
ta
ti
o
n 
si
te
s,
 
es
ti
m
at
e 
(9
5%
 C
I)
G
ro
up
–t
im
e 
in
te
ra
ct
io
n,
 
es
ti
m
at
e 
(9
5%
 C
I)
P
 v
al
ue
 f
o
r 
in
te
ra
ct
io
n 
te
rm
C
O
P
D
 r
ea
d
m
is
si
on
 w
ith
in
 2
8 
d
ay
s
U
na
d
ju
st
ed
19
 0
97
O
R
=
0.
97
 (0
.8
4 
to
 1
.1
1)
O
R
=
0.
94
 (0
.8
1 
to
 1
.1
0)
O
R
=
0.
97
 (0
.7
9 
to
 1
.2
0)
0.
80
4
A
d
ju
st
ed
*
18
 3
24
O
R
=
0.
93
 (0
.8
1 
to
 1
.0
7)
O
R
=
0.
95
 (0
.8
1 
to
 1
.1
1)
O
R
=
1.
02
 (0
.8
3 
to
 1
.2
6)
0.
86
5
A
ll-
ca
us
e 
re
ad
m
is
si
on
 w
ith
in
 
28
 d
ay
s
U
na
d
ju
st
ed
17
 7
42
O
R
=
1.
02
 (0
.9
1 
to
 1
.1
4)
O
R
=
0.
86
 (0
.7
6 
to
 0
.9
8)
O
R
=
0.
85
 (0
.7
1 
to
 1
.0
1)
0.
06
0
A
d
ju
st
ed
*
16
 9
81
O
R
=
1.
00
 (0
.8
8 
to
 1
.1
2)
O
R
=
0.
88
 (0
.7
7 
to
 1
.0
0)
O
R
=
0.
88
 (0
.7
4 
to
 1
.0
5)
0.
15
6
C
O
P
D
 r
ea
d
m
is
si
on
 w
ith
in
 9
0 
d
ay
s†
U
na
d
ju
st
ed
18
 3
81
IR
R
=
0.
99
 (0
.9
5 
to
 1
.0
3)
IR
R
=
0.
98
 (0
.8
4 
to
 1
.1
5)
IR
R
=
0.
99
 (0
.8
4 
to
 1
.1
6)
0.
89
9
A
d
ju
st
ed
*
17
 6
34
IR
R
=
0.
98
 (0
.9
5 
to
 1
.0
1)
IR
R
=
0.
99
 (0
.8
6 
to
 1
.1
3)
IR
R
=
1.
00
 (0
.8
7 
to
 1
.1
6)
0.
97
1
Le
ng
th
 o
f s
ta
y 
fo
r 
C
O
P
D
 
ad
m
is
si
on
U
na
d
ju
st
ed
19
 3
43
IR
R
=
0.
99
 (0
.9
4 
to
 1
.0
4)
IR
R
=
0.
93
 (0
.8
8 
to
 0
.9
7)
IR
R
=
0.
94
 (0
.8
8 
to
 1
.0
1)
0.
07
1
A
d
ju
st
ed
*
18
 5
65
IR
R
=
0.
98
 (0
.9
4 
to
 1
.0
3)
IR
R
=
0.
93
 (0
.8
8 
to
 0
.9
7)
IR
R
=
0.
94
 (0
.8
8 
to
 1
.0
1)
0.
10
0
N
um
b
er
 o
f e
m
er
ge
nc
y 
d
ep
ar
tm
en
t 
at
te
nd
an
ce
s
U
na
d
ju
st
ed
15
 6
46
IR
R
=
1.
14
 (1
.0
4 
to
 1
.2
6)
IR
R
=
0.
63
 (0
.5
6 
to
 0
.7
0)
IR
R
=
0.
55
 (0
.4
7 
to
 0
.6
3)
<
0.
00
1
A
d
ju
st
ed
*
14
 9
00
IR
R
=
1.
12
 (1
.0
2,
 1
.2
4)
IR
R
=
0.
63
 (0
.5
6 
to
 0
.7
1)
IR
R
=
0.
56
 (0
.4
8 
to
 0
.6
5)
<
0.
00
1
In
-h
os
p
ita
l m
or
ta
lit
y 
fo
r 
C
O
P
D
 
ad
m
is
si
on
s
U
na
d
ju
st
ed
19
 3
43
O
R
=
0.
79
 (0
.6
4 
to
 0
.9
8)
O
R
=
0.
79
 (0
.6
3 
to
 0
.9
9)
O
R
=
1.
00
 (0
.7
4 
to
 1
.3
6)
0.
99
2
A
d
ju
st
ed
*
18
 5
65
O
R
=
0.
78
 (0
.6
3 
to
 0
.9
7)
O
R
=
0.
82
 (0
.6
5 
to
 1
.0
3)
O
R
=
1.
05
 (0
.7
7 
to
 1
.4
4)
0.
74
1
90
-d
ay
 m
or
ta
lit
y†
U
na
d
ju
st
ed
17
 6
64
IR
R
=
0.
93
 (0
.7
8 
to
 1
.1
0)
IR
R
=
0.
89
 (0
.7
3 
to
 1
.0
8)
IR
R
=
0.
96
 (0
.7
4 
to
 1
.2
4)
0.
73
4
A
d
ju
st
ed
16
 9
44
IR
R
=
0.
93
 (0
.8
0 
to
 1
.0
8)
IR
R
=
0.
93
 (0
.7
9 
to
 1
.1
1)
IR
R
=
1.
01
 (0
.8
0 
to
 1
.2
6)
0.
94
6
*A
d
ju
st
ed
 fo
r 
ag
e,
 s
ex
, e
th
ni
ci
ty
 a
nd
 IM
D
 q
ui
nt
ile
.
†C
I c
al
cu
la
te
d
 u
si
ng
 r
ob
us
t 
S
E
s;
 t
he
 W
al
d
 t
es
t 
w
as
 u
se
d
 t
o 
ge
ne
ra
te
 t
he
 p
 v
al
ue
 fo
r 
in
te
ra
ct
io
n.
C
O
P
D
, c
hr
on
ic
 o
b
st
ru
ct
iv
e 
p
ul
m
on
ar
y 
d
is
ea
se
; I
M
D
, I
nd
ex
 o
f M
ul
tip
le
 D
ep
riv
at
io
n;
 IR
R
, i
nc
id
en
ce
 r
at
e 
ra
tio
.
 o
n
 25 June 2019 by guest. Protected by copyright.
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2019-000425 on 30 May 2019. Downloaded from 
Morton K, et al. BMJ Open Resp Res 2019;6:e000425. doi:10.1136/bmjresp-2019-000425 7
Open access
Table 4 Delivery of individual elements of the admissions bundle at level 2 comparator and implementation sites
Admissions bundle
Bundle element Delivery
Comparator 
sites, n (%)
Implementation 
sites, n (%) P value
1. Correct diagnosis of AECOPD.
  1a. Chest X-ray result within 4 hours. Yes 443 (76.8) 454 (83.9) 0.003
  1b. ECG result within 4 hours. Yes 473 (74.8) 656 (83.5) <0.001
  1a and 1b Yes 350 (59.9) 382 (66.4) 0.022
2. Recognise and respond to respiratory acidosis within 3 hours of diagnosis.
  2a. Arterial blood gas within 1 hour if oxygen sats less than 94% 
on air or controlled oxygen.
Yes 403 (75.6) 467 (73.8) 0.473
  2b. When pH is less than 7.35, assess suitability for Non-invasive 
ventilation (NIV) and implement within 3 hours of admission.
Yes 345 (94.5) 492 (98.0) 0.006
  2a and 2b Yes 193 (57.4) 283 (61.9) 0.203
3. Recognition of hypoxia and correct oxygen prescription within 30 min of admission with target range of 88%–92%.
 Yes 197 (32.5) 395 (51.7) <0.001
4. Correct prescription of medication for AECOPD at admission.
  4a. Steroids prescribed and administered within 4 hours of 
admission when necessary.
Yes 479 (80.6) 496 (70.2) <0.001
  4b. Antibiotics prescribed and administered within 4 hours of 
admission when necessary.
Yes 445 (73.4) 535 (74.6) 0.624
  4c. Nebulisers prescribed and administered within 1 hour of 
admission when necessary.
Yes 327 (52.2) 315 (43.5) 0.002
  4a, 4b and 4c Yes 214 (35.8) 207 (29.5) 0.015
5. Review by respiratory specialist (specialist nurse, doctor or physiotherapist) within 24 hours.
 Yes 100 (17.4) 274 (39.3) <0.001
AECOPD, acute exacerbation of chronic obstructive pulmonary disease.
DIscussIon
We found no evidence that change in readmissions over 
time differed between implementation and compar-
ator sites. Furthermore, no difference was observed for 
in-hospital mortality, length of stay or 90-day readmis-
sion. There was a reduction in ED attendances for those 
receiving care in implementation sites. Additionally, there 
was a small reduction in the duration of hospital stay for 
patients in the implementation group. The implementa-
tion of care bundles was unlikely to be cost-effective from 
a secondary care perspective.
Qualitative data suggested that health professionals 
valued bundles as a means of focusing on standardised 
quality of care, but staff lacked experience and knowl-
edge in QI strategies. This reflects the findings of Lennox 
et al,23 who identify the barriers and facilitators to care 
bundle implementation. As other authors have identi-
fied, the local context, governance structures and finan-
cial incentives for support were crucial in determining 
whether, and how effectively, sites implemented care 
bundles.24 We observed the use of discharge ‘checklists’ 
at comparator sites, which often represented ‘bundling 
by another name’. As a result, similar processes and activ-
ities seemed to be taking place at implementation and 
comparator sites. This is likely to have reduced the ability 
of the study to demonstrate difference in outcomes 
attributable to care bundles.
To achieve improvements in outcomes, care bundles 
must meet three criteria: the target outcome must be 
sensitive to change and responsive to the elements 
within the bundle; the care bundles must be reliably 
implemented to ensure that the majority of patients 
receive bundle-led care; and use of the care bundle must 
improve process reliability.13 In this study the bundles 
were not delivered reliably, with delivery of the full five-
item admission bundle and discharge bundle being very 
low, although there is some evidence from our data that 
those patients in receipt of a bundle received more of 
the required elements of care, suggesting some improve-
ment in process reliability. The third criterion was not 
met since most patients did not receive the full set of 
bundle elements. Therefore, effective implementation 
of the admission and discharge bundles did not occur 
and the anticipated difference between groups was not 
observed.
The original BTS COPD care bundles project 
included QI methodology and continuous data collec-
tion to ensure compliance with elements of bundle 
delivery.7 13 However, few sites fully engaged with this 
process during this study, and it was clear from site visits 
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Table 5 Delivery of individual elements of the discharge bundle at level 2 comparator and implementation sites
Discharge bundle
Bundle element Delivery
Comparator 
sites, n (%)
Implementation 
sites, n (%) P value
1. Assess respiratory medications and inhaler technique.
  1a. Respiratory medications. Yes 342 (53.4) 542 (68.5) <0.001
  1b. Inhaler technique. Yes 106 (17.1) 307 (40.4) <0.001
  1a and 1b Yes 102 (16.1) 302 (39.4) <0.001
2. All patients should receive
  2a. Written pack about managing further AECOPD. Yes/not applicable 253 (39.6) 404 (51.5) <0.001
  2b. Discharge pack of emergency medications. Yes/not applicable 170 (26.4) 573 (73.6) <0.001
  2a and 2b Yes 133 (20.6) 352 (45.3) <0.001
3. Assess smoking status and willingness to quit.
 Smoker but cessation 
not discussed
124 (23.4) 102 (14.4) <0.001
Smoker/ex-smoker and 
cessation discussed
68 (12.8) 173 (24.4)
Never smoker/ex-
smoker
338 (63.8) 435 (61.3)
4. Assess for suitability of pulmonary rehabilitation prior to discharge.
 Yes/completed rehab 
previously/declined or 
not applicable
172 (26.4) 407 (51.6) <0.001
5. Organise community follow-up within 2 weeks of discharge from hospital.
 Yes, declined or not 
applicable
356 (54.9) 555 (70.3) <0.001
AECOPD, acute exacerbation of chronic obstructive pulmonary disease.
that staff had insufficient time to change processes of 
care reliably.
strengths and limitations
Due to the timing of care bundle implementation 
nationally, it was not possible to undertake a randomised 
controlled trial to evaluate the impact of care bundles. 
While site recruitment was facilitated through several 
routes, it is possible that the participating sites were 
those with a respiratory team who had an interest in 
care bundles or research activity related to COPD. Thus, 
they may have demonstrated ‘better’ performance with 
regard to COPD care and QI than average, introducing 
recruitment bias to the study.
Conducting research in the context of acute admis-
sions posed challenges to patient recruitment and data 
collection, particularly in terms of data availability and 
completeness. Additional limitations of the study include 
potential reporting bias as some sites were unable to 
provide useful level 1 and 2 data. There were also differ-
ences in patient populations at different sites and imple-
mentation sites had higher baseline COPD readmission 
rates, and these factors could possibly have influenced 
the outcomes of the study.
With regard to the finding of a greater reduction 
in ED attendances in implementation sites than in 
comparator sites, we cannot exclude the possibility that 
this result arose by chance. A recent systematic review 
found only one study that considered the impact of 
COPD care bundles on ED attendances and found no 
effect.12
These findings benefit from the pragmatic study 
design and robust analysis of detailed data from an 
extensive range of hospitals in England and Wales, 
enabling assessment of the delivery of care bundles in a 
‘real-life’ care delivery context. Using a mixed-methods 
approach has ensured both the perception and prac-
tice of implementation have been evaluated. The find-
ings are not necessarily due to lack of effectiveness of 
COPD bundles; rather they are likely due to lack of 
effective implementation of COPD bundles. This does 
not limit the importance of the results but highlights 
the ‘real life’ challenge of incorporating improvement 
science methods alongside reliable implementation of 
standard processes.
Future research should aim to address the temporality 
of QI practices through a longitudinal study offering 
greater and indepth analysis of the QI life cycle. Closer 
monitoring of implementation reliability would also be 
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beneficial, ensuring that any observed lack of effect is 
related to the efficacy of the intervention rather than 
failure of implementation. The fields of improvement 
science and implementation research offer insights into 
more effective ways of facilitating QI in the NHS.25 Using 
these to ensure that QI efforts are as evidence-based as 
the best practice they seek to implement would enable 
future QI projects to make changes in the most effective 
way.
In summary, COPD care bundles had little impact on 
patient outcomes but appeared to be associated with a 
reduced number of subsequent ED attendances. The 
distinction between bundle implementation and stan-
dard care was not clearly defined and fidelity with care 
bundle delivery was generally very low, although care 
bundles had some impact on improving process reli-
ability. These findings are unsurprising given the low level 
of bundle uptake in implementation sites, and it remains 
to be determined if COPD care bundles affect patient 
care and outcomes when they are effectively imple-
mented. Healthcare professionals value care bundles, but 
despite the simplicity of the approach they are complex 
to implement, and clinicians require support to success-
fully change care pathways.
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